Details for Patent: 10,610,125

Which drugs does patent 10,610,125 protect, and when does it expire?

Patent 10,610,125 protects IDHIFA and TIBSOVO and is included in two NDAs.

This patent has fourteen patent family members in eight countries.

Summary for Patent: 10,610,125

Patent landscape, scope, and claims:

Title:	Methods and compositions for cell-proliferation-related disorders
Abstract:	Methods of treating and evaluating subjects having neoactive mutants are described herein.
Inventor(s):	Dang; Lenny (Boston, MA), Fantin; Valeria (Burlingame, CA), Gross; Stefan (Brookline, MA), Jang; Hyun Gyung (Waltham, MA), Jin; Shengfang (Newton, MA), Salituro; Francesco G. (Marlborough, MA), Saunders; Jeffrey O. (Lincoln, MA), Su; Shin-San Michael (Boston, MA), Yen; Katharine (Wellesley, MA)
Assignee:	Agios Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	15/589,615
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,610,125
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,610,125

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol Myers Squibb	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-001	Aug 1, 2017		RX	Yes	No						TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION
Bristol Myers Squibb	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-002	Aug 1, 2017		RX	Yes	Yes						TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION
Servier	TIBSOVO	ivosidenib	TABLET;ORAL	211192-001	Jul 20, 2018		RX	Yes	Yes						A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) AND WHERE THE MUTANT IDH1 HAS THE ABILITY TO CONVERT ALPHA-KETOGLUTARATE INTO 2-HYDROXYGLUTARATE (2-HG)
Servier	TIBSOVO	ivosidenib	TABLET;ORAL	211192-001	Jul 20, 2018		RX	Yes	Yes						A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) AND WHERE THE MUTANT IDH1 HAS THE ABILITY TO CONVERT ALPHA-KETOGLUTARATE INTO 2-HYDROXYGLUTARATE (2-HG)
Servier	TIBSOVO	ivosidenib	TABLET;ORAL	211192-001	Jul 20, 2018		RX	Yes	Yes						A METHOD FOR TREATING NEWLY DIAGNOSED AML WITH IVOSIDENIB AND AZACITIDINE WHEREIN THE AML HAS AN IDH1 MUTATION CAPABLE OF CONVERTING ALPHA-KETOGLUTARATE TO 2-HYDROXYGLUTARATE (2HG)

International Family Members for US Patent 10,610,125

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010223919
Australia	2016204346
Canada	2755394
China	102985557
China	108524505